OpenLB
Open Library of Bioscience
Advanced Search
NPJ vaccines
Nov 14, 2024;9 (1): 218.

Mapping global public perspectives on mRNA vaccines and therapeutics.

Jiaxiang Xu, Zhengdong Wu, Lily Wass, Heidi J Larson, Leesa Lin
Author Information
  1. Jiaxiang Xu: Laboratory of Data Discovery for Health Limited (D24H), Hong Kong Science Park, Hong Kong SAR, China. ORCID
  2. Zhengdong Wu: Laboratory of Data Discovery for Health Limited (D24H), Hong Kong Science Park, Hong Kong SAR, China.
  3. Lily Wass: Laboratory of Data Discovery for Health Limited (D24H), Hong Kong Science Park, Hong Kong SAR, China. ORCID
  4. Heidi J Larson: Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK. ORCID
  5. Leesa Lin: Laboratory of Data Discovery for Health Limited (D24H), Hong Kong Science Park, Hong Kong SAR, China. Leesa.Lin@lshtm.ac.uk. ORCID
PMID: 39543153 DOI: 10.1038/s41541-024-01019-3

Abstract

The development and rollout of mRNA vaccines during COVID-19 marked a significant advancement in vaccinology, yet public hesitation to vaccination was prevalent, indicating the potential risk that future mRNA-based medical innovations will fail to be adopted. Utilizing a combined approach of large language models with manual validation and unsupervised machine learning, we conducted a social listening analysis to assess attitudes towards mRNA vaccines and therapeutics on Twitter from June 2022 to May 2023, contrasting online perspectives with data from the Vaccine Adverse Event Reporting System. Our findings reveal widespread negative sentiment and a global lack of confidence in the safety, effectiveness, and trustworthiness of mRNA vaccines and therapeutics, with frequent discussions of severe vaccine side effects, rumors, and misinformation. This underscores the need for targeted communication strategies to foster acceptance of medical treatments and strengthen public trust in order to enhance societal resilience to future health challenges.

References

  1. J Med Internet Res. 2021 Oct 21;23(10):e30765 [PMID: 34581682]
  2. J Med Internet Res. 2022 Jul 13;24(7):e37142 [PMID: 35731966]
  3. JAMA Netw Open. 2020 Jun 1;3(6):e208953 [PMID: 32584408]
  4. Vaccines (Basel). 2022 Mar 22;10(4): [PMID: 35455237]
  5. JMIR Infodemiology. 2023 Nov 30;3:e43700 [PMID: 37903294]
  6. Commun Med (Lond). 2022 Feb 10;2:14 [PMID: 35603311]
  7. JMIR Hum Factors. 2022 Dec 2;9(4):e38799 [PMID: 36459412]
  8. BMJ. 2024 Jan 16;384:e076542 [PMID: 38228339]
  9. JMIR Public Health Surveill. 2022 May 27;8(5):e32543 [PMID: 35144240]
  10. J Med Internet Res. 2022 Feb 8;24(2):e31726 [PMID: 34783665]
  11. Vaccine. 2015 Aug 26;33(36):4398-405 [PMID: 26209838]
  12. Nat Hum Behav. 2021 Mar;5(3):337-348 [PMID: 33547453]
  13. JMIR Public Health Surveill. 2023 Jul 3;9:e42958 [PMID: 37247615]
  14. BMJ. 2024 Jan 16;384:q69 [PMID: 38228351]
  15. Nature. 2021 Sep;597(7876):318-324 [PMID: 34522017]
  16. JMIR Form Res. 2022 Sep 15;6(9):e37775 [PMID: 36007136]
  17. PLoS One. 2021 Nov 17;16(11):e0258462 [PMID: 34788308]
  18. Front Public Health. 2021 Jul 16;9:695807 [PMID: 34336774]
  19. J Med Internet Res. 2022 Oct 31;24(10):e37258 [PMID: 36219757]
  20. Hum Vaccin Immunother. 2022 Nov 30;18(6):2138047 [PMID: 36345571]
  21. Vaccine. 2021 Apr 8;39(15):2060-2067 [PMID: 33741191]
  22. Vaccine. 2015 Aug 14;33(34):4161-4 [PMID: 25896383]
  23. Sci Rep. 2022 Apr 26;12(1):5966 [PMID: 35474313]
  24. J Med Internet Res. 2021 Jun 11;23(6):e27632 [PMID: 34061757]
  25. AIDS. 2018 Nov 13;32(17):2533-2545 [PMID: 30289805]
  26. Vaccine. 2023 Jul 25;41(33):4844-4853 [PMID: 37385887]
  27. Nat Biotechnol. 2022 Jun;40(6):840-854 [PMID: 35534554]
  28. J Med Internet Res. 2021 May 20;23(5):e26933 [PMID: 33882014]
  29. MMWR Morb Mortal Wkly Rep. 2022 Apr 08;71(14):517-523 [PMID: 35389977]
  30. Am J Public Health. 2017 Jan;107(1):e1-e8 [PMID: 27854532]
  31. Sci Rep. 2022 Jan 28;12(1):1554 [PMID: 35091640]
  32. Nat Rev Drug Discov. 2018 Apr;17(4):261-279 [PMID: 29326426]
  33. Commun Med (Lond). 2022 May 31;2:61 [PMID: 35664455]
  34. Hum Vaccin Immunother. 2022 Dec 30;18(7):2145822 [PMID: 36452995]
  35. Vaccines (Basel). 2021 Mar 29;9(4): [PMID: 33805283]
  36. Hum Vaccin Immunother. 2020 Nov 1;16(11):2586-2593 [PMID: 32693678]
  37. J Med Internet Res. 2021 Jun 29;23(6):e24435 [PMID: 34115608]
  38. J Med Internet Res. 2023 Feb 24;25:e42227 [PMID: 36735835]
  39. Vaccine. 2017 Aug 16;35(35 Pt B):4494-4498 [PMID: 28736200]
  40. Vaccines (Basel). 2022 Aug 02;10(8): [PMID: 36016126]
  41. Curr Opin Infect Dis. 2023 Oct 1;36(5):385-393 [PMID: 37462930]
  42. Nat Med. 2021 Dec;27(12):2136-2143 [PMID: 34728831]
  43. Health Aff (Millwood). 2016 Feb;35(2):341-7 [PMID: 26858390]
Journal Article
Article has an altmetric score of 8

Word Cloud

Created with Highcharts 10.0.0mRNAvaccinespublictherapeuticsfuturemedicalperspectivesglobaldevelopmentrolloutCOVID-19markedsignificantadvancementvaccinologyyethesitationvaccinationprevalentindicatingpotentialriskmRNA-basedinnovationswillfailadoptedUtilizingcombinedapproachlargelanguagemodelsmanualvalidationunsupervisedmachinelearningconductedsociallisteninganalysisassessattitudestowardsTwitterJune2022May2023contrastingonlinedataVaccineAdverseEventReportingSystemfindingsrevealwidespreadnegativesentimentlackconfidencesafetyeffectivenesstrustworthinessfrequentdiscussionsseverevaccinesideeffectsrumorsmisinformationunderscoresneedtargetedcommunicationstrategiesfosteracceptancetreatmentsstrengthentrustorderenhancesocietalresiliencehealthchallengesMapping

Similar Articles

Cited By (2)